Growth rebound after termination of stimulant drugs

Research output: Contribution to journalArticle

Abstract

To explore further the report1 of an accelerated weight gain following termination of treatment with a stimulant drug, 66 biannual growth measurements were obtained from 1970 to 1973 on hyperactive schoolchildren who were receiving medication. All received either dextroamphetamine or methylphenidate during the school year; some also received it during the summer. The data revealed that those whose stimulant medication was terminated at the start of summer subsequently grew in weight and height at a significantly greater rate than those who continued to receive medication from June to September. In fact, discontinuance of the medication resulted in a growth rebound for this period which was 15-68% above the age-expected increment.

Original languageEnglish (US)
Pages (from-to)113-116
Number of pages4
JournalJournal of Pediatrics
Volume86
Issue number1
DOIs
StatePublished - 1975

Fingerprint

Dextroamphetamine
Methylphenidate
Growth
Pharmaceutical Preparations
Weight Gain
Weights and Measures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Growth rebound after termination of stimulant drugs. / Safer, Daniel J.; Allen, Richard; Barr, Evelyn.

In: Journal of Pediatrics, Vol. 86, No. 1, 1975, p. 113-116.

Research output: Contribution to journalArticle

@article{c5367c098b1341e9bb93fb9f643db7b0,
title = "Growth rebound after termination of stimulant drugs",
abstract = "To explore further the report1 of an accelerated weight gain following termination of treatment with a stimulant drug, 66 biannual growth measurements were obtained from 1970 to 1973 on hyperactive schoolchildren who were receiving medication. All received either dextroamphetamine or methylphenidate during the school year; some also received it during the summer. The data revealed that those whose stimulant medication was terminated at the start of summer subsequently grew in weight and height at a significantly greater rate than those who continued to receive medication from June to September. In fact, discontinuance of the medication resulted in a growth rebound for this period which was 15-68{\%} above the age-expected increment.",
author = "Safer, {Daniel J.} and Richard Allen and Evelyn Barr",
year = "1975",
doi = "10.1016/S0022-3476(75)80720-7",
language = "English (US)",
volume = "86",
pages = "113--116",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Growth rebound after termination of stimulant drugs

AU - Safer, Daniel J.

AU - Allen, Richard

AU - Barr, Evelyn

PY - 1975

Y1 - 1975

N2 - To explore further the report1 of an accelerated weight gain following termination of treatment with a stimulant drug, 66 biannual growth measurements were obtained from 1970 to 1973 on hyperactive schoolchildren who were receiving medication. All received either dextroamphetamine or methylphenidate during the school year; some also received it during the summer. The data revealed that those whose stimulant medication was terminated at the start of summer subsequently grew in weight and height at a significantly greater rate than those who continued to receive medication from June to September. In fact, discontinuance of the medication resulted in a growth rebound for this period which was 15-68% above the age-expected increment.

AB - To explore further the report1 of an accelerated weight gain following termination of treatment with a stimulant drug, 66 biannual growth measurements were obtained from 1970 to 1973 on hyperactive schoolchildren who were receiving medication. All received either dextroamphetamine or methylphenidate during the school year; some also received it during the summer. The data revealed that those whose stimulant medication was terminated at the start of summer subsequently grew in weight and height at a significantly greater rate than those who continued to receive medication from June to September. In fact, discontinuance of the medication resulted in a growth rebound for this period which was 15-68% above the age-expected increment.

UR - http://www.scopus.com/inward/record.url?scp=0016428244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016428244&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(75)80720-7

DO - 10.1016/S0022-3476(75)80720-7

M3 - Article

C2 - 1110433

AN - SCOPUS:0016428244

VL - 86

SP - 113

EP - 116

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -